Zhong et al. [115] reported that in BC, doxycycline exerts its inhibitory effects via a miR-17-dependent pathway, where doxycycline binds to PAR1, inactivating NF-κB and downregulating miR-17, resulting in an upregulation of E-cadherin and an inhibition of EMT progression, decreasing BC migration. The gene discussed is NFKB1; the disease is breast cancer.